109 related articles for article (PubMed ID: 9384230)
1. Comparison of the antiplatelet effect of YM337 and abciximab in rhesus monkeys.
Suzuki K; Sakai Y; Hisamichi N; Taniuchi Y; Sato K; Terazaki C; Kaku S; Kawasaki T; Yano S; Inagaki O; Masuho Y
Eur J Pharmacol; 1997 Oct; 336(2-3):169-76. PubMed ID: 9384230
[TBL] [Abstract][Full Text] [Related]
2. Antiplatelet and antithrombotic effects of YM337, the Fab fragment of a humanized anti-GPIIb/IIIa monoclonal antibody in monkeys.
Kaku S; Kawasaki T; Hisamichi N; Sakai Y; Taniuchi Y; Inagaki O; Yano S; Suzuki K; Terazaki C; Masuho Y; Satoh N; Takenaka T; Yanagi K; Ohshima N
Thromb Haemost; 1996 Apr; 75(4):679-84. PubMed ID: 8743199
[TBL] [Abstract][Full Text] [Related]
3. Comparative studies of a humanized anti-glycoprotein IIb/IIIa monoclonal antibody, YM337, and abciximab on in vitro antiplatelet effect and binding properties.
Suzuki K; Sato K; Kamohara M; Kaku S; Kawasaki T; Yano S; Iizumi Y
Biol Pharm Bull; 2002 Aug; 25(8):1006-12. PubMed ID: 12186399
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamic effects of a new antibody glycoprotein IIb/IIIa inhibitor (YM337) in healthy subjects.
Harder S; Kirchmaier CM; Krzywanek HJ; Westrup D; Bae JW; Breddin HK
Circulation; 1999 Sep; 100(11):1175-81. PubMed ID: 10484537
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by combination with a humanized anti-glycoprotein IIb/IIIa monoclonal antibody, YM337, in a rhesus monkey model of coronary thrombosis.
Kawasaki T; Sato K; Suzuki K; Sakai Y; Taniuchi Y; Kaku S; Yano S; Inagaki O; Tomioka K; Masuho Y; Yanagisawa I; Takenaka T
Thromb Haemost; 1998 Mar; 79(3):663-7. PubMed ID: 9531059
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the antiplatelet agent potential of the whole molecule, F(ab)2 and Fab fragments of humanized anti-GPIIb/IIIa monoclonal antibody in monkeys.
Kaku S; Yano S; Kawasaki T; Sakai Y; Suzuki K; Kawamura K; Masuho Y; Satoh N; Takenaka T; Landolfi NF; Co MS
Gen Pharmacol; 1996 Apr; 27(3):435-9. PubMed ID: 8723521
[TBL] [Abstract][Full Text] [Related]
7. Occupancy of the internal and external pools of glycoprotein IIb/IIIa following abciximab bolus and infusion.
Quinn MJ; Murphy RT; Dooley M; Foley JB; Fitzgerald DJ
J Pharmacol Exp Ther; 2001 May; 297(2):496-500. PubMed ID: 11303035
[TBL] [Abstract][Full Text] [Related]
8. Effects of GP IIb/IIIa receptor monoclonal antibody (7E3), heparin, and aspirin in an ex vivo canine arteriovenous shunt model of stent thrombosis.
Makkar RR; Litvack F; Eigler NL; Nakamura M; Ivey PA; Forrester JS; Shah PK; Jordan RE; Kaul S
Circulation; 1997 Feb; 95(4):1015-21. PubMed ID: 9054765
[TBL] [Abstract][Full Text] [Related]
9. Blockade of the human platelet GPIIb/IIIa receptor by a murine monoclonal antibody Fab fragment (7E3): potent dose-dependent inhibition of platelet function.
Bhattacharya S; Jordan R; Machin S; Senior R; Mackie I; Smith CR; Schaible TF; Weisman HF; Lahiri A
Cardiovasc Drugs Ther; 1995 Oct; 9(5):665-75. PubMed ID: 8573549
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamics of abciximab during angioplasty: comparison to healthy subjects.
Abernethy DR; Pezzullo J; Mascelli MA; Frederick B; Kleiman NS; Freedman J
Clin Pharmacol Ther; 2002 Mar; 71(3):186-95. PubMed ID: 11907493
[TBL] [Abstract][Full Text] [Related]
11. Quantifying GPIIb/IIIa receptor binding using 2 monoclonal antibodies: discriminating abciximab and small molecular weight antagonists.
Quinn M; Deering A; Stewart M; Cox D; Foley B; Fitzgerald D
Circulation; 1999 May; 99(17):2231-8. PubMed ID: 10226086
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic characterization of the interaction between the glycoprotein IIb/IIIa inhibitor YM337 and unfractionated heparin and aspirin in humans.
Graff J; Klinkhardt U; Westrup D; Kirchmaier CM; Breddin HK; Harder S
Br J Clin Pharmacol; 2003 Sep; 56(3):321-6. PubMed ID: 12919181
[TBL] [Abstract][Full Text] [Related]
13. Comparative real-time effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb-IIIa.
Turner NA; Moake JL; Kamat SG; Schafer AI; Kleiman NS; Jordan R; McIntire LV
Circulation; 1995 Mar; 91(5):1354-62. PubMed ID: 7867173
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of AJW200, a humanized monoclonal antibody to von Willebrand factor, in monkeys.
Kageyama S; Yamamoto H; Nakazawa H; Matsushita J; Kouyama T; Gonsho A; Ikeda Y; Yoshimoto R
Arterioscler Thromb Vasc Biol; 2002 Jan; 22(1):187-92. PubMed ID: 11788481
[TBL] [Abstract][Full Text] [Related]
15. Effect of a humanized monoclonal antibody to von Willebrand factor in a canine model of coronary arterial thrombosis.
Kageyama S; Matsushita J; Yamamoto H
Eur J Pharmacol; 2002 May; 443(1-3):143-9. PubMed ID: 12044804
[TBL] [Abstract][Full Text] [Related]
16. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
Gawaz M; Ruf A; Pogatsa-Murray G; Dickfeld T; Rüdiger S; Taubitz W; Fischer J; Müller I; Meier D; Patscheke H; Schömig A
Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic and clinical trials of glycoprotein IIb/IIIa inhibitors and potential relationship of results to dosing.
Hobbach HP; Schuster P
Z Kardiol; 2003 Mar; 92(3):213-8. PubMed ID: 12658467
[TBL] [Abstract][Full Text] [Related]
18. Anti-human vWF monoclonal antibody, AJvW-2 Fab, inhibits repetitive coronary artery thrombosis without bleeding time prolongation in dogs.
Kageyama S; Yamamoto H; Nakazawa H; Yoshimoto R
Thromb Res; 2001 Mar; 101(5):395-404. PubMed ID: 11297756
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade.
Mascelli MA; Lance ET; Damaraju L; Wagner CL; Weisman HF; Jordan RE
Circulation; 1998 May; 97(17):1680-8. PubMed ID: 9591761
[TBL] [Abstract][Full Text] [Related]
20. IIb's are not IIb's.
Kereiakes DJ; Runyon JP; Broderick TM; Shimshak TM
Am J Cardiol; 2000 Apr; 85(8A):23C-31C. PubMed ID: 10793177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
